Dow Jones
37.989,37 -471,55 (-1,23%) Nasdaq
15.530,86 -181,89 (-1,16%) Nikkei 225
37.628,48 -831,60 (-2,16%) EUR/USD
1,0737 +0,0036 (+0,33%) Bitcoin EUR
59.943,89 -288,40 (-0,48%) CMC Crypto 200
1.385,86 +3,28 (+0,24%)
PCI Biotech Holding ASA (0JGL.L)
| Chiusura precedente | 2,5900 |
| Aperto | 0,0000 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,0000 - 0,0000 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 1,62 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,3480 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswirePCI Biotech initiates field testing of its proprietary technology for gene therapy manufacturing
Oslo, Norway, 13 October 2023 – PCI Biotech (OSE: PCIB) today announced a research collaboration agreement with the aim to address critical pain points in the manufacturing of gene therapies. The partners have signed a collaborative research agreement with the purpose of testing PCI Biotech’s proprietary technology for gene therapy manufacturing in the partners’ pilot manufacturing process. PCI Biotech brings its novel and promising technology for viral vector manufacturing into the field testin
- GlobeNewswire
PCI Biotech: European patent for mRNA delivery with fimaNAc
Oslo (Norway), 7 September 2023 – PCI Biotech (OSE: PCIB), a biopharmaceutical company, today announces that the European Patent Office (EPO) has informed PCI Biotech that they intend to grant a new patent covering delivery of mRNA by use of PCI Biotech’s fimaNAc technology. This application is primarily foreseen to be used for dermatology. Nucleic acid therapeutics, including mRNAs, have the potential to improve the treatment of dermatological diseases, but delivery to skin lesions remains an o
- GlobeNewswire
PCI Biotech: Employee share option scheme
Oslo, 4 September 2023 - PCI Biotech (OSE: PCIB), today announce that the Board of Directors has granted share options to key employees. In accordance with the authorisation granted by the Annual General Meeting 25 May 2023 and the remuneration policy adopted by the Annual General Meeting 28 May 2021, the Board of Directors of PCI Biotech Holding ASA (“PCI Biotech”) has awarded a total of 700,000 share options to key employees. Each share option gives the right to subscribe for or acquire one sh
